Original language | English |
---|---|
Pages (from-to) | 9046 |
Number of pages | 1 |
Journal | Journal of Clinical Oncology |
Volume | 39 |
DOIs | |
Publication status | Published - 20 May 2021 |
Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.
Timothy Clay, Margarita Majem, Enriqueta Felip, Bernard Doger, Enric Carcereny, Martin Forster, Matthew Krebs, Julio Peguero, Christian Mueller, Frederic Triebel
Research output: Contribution to journal › Meeting Abstract › peer-review